Plus Therapeutics shares fall 17.00% after-hours as FY 2025 net loss surges 72% to $22.39 million.

Plus Therapeutics (PSTV) fell 17.00% in after-hours trading following the release of its FY 2025 financial results, which revealed a 72% year-over-year increase in net loss to $22.39 million and a $15.3 million operating loss. The company attributed the widening losses to expanded operations and anticipated higher R&D and general/administrative expenses in 2026. Despite a Q4 revenue beat of $5.21 million and a modest EPS surprise, the significant deterioration in profitability and guidance for escalating costs overshadowed short-term gains, triggering a sharp sell-off. The after-hours decline reflects investor concerns over the company’s path to profitability amid growing cash burn and operational scaling.